TABLE 2.
Results of the multivariable Cox regression analysis for influence of suPAR on mortality after serum collection date.
| Subpopulation | N | HR | 95% CI | p-value |
|---|---|---|---|---|
| All study patients | 1,023 | 2.14 | 1.48–3.08 | <0.001 |
| Death due to CVD | 4.24 | 1.81–9.96 | <0.001 | |
| Death due to infection | 2.20 | 0.90–5.39 | 0.083 | |
| Death due to cancer | 1.61 | 0.53–4.91 | 0.40 | |
| Cohort 1 | 474 | 1.92 | 1.20–3.08 | 0.007 |
| Cohort 2 | 549 | 2.78 | 1.51–5.13 | 0.001 |
| Good kidney function | 255 | 5.40 | 1.42–20.5 | 0.013 |
| Female patients | 388 | 1.91 | 0.97–3.76 | 0.061 |
| Male patients | 635 | 2.41 | 1.56–3.73 | <0.001 |
| Young patients <50 years | 584 | 3.38 | 1.81–6.34 | <0.001 |
| Elderly patients ≥50 years | 439 | 1.73 | 1.10–2.71 | 0.017 |
Hazard ratios (HR) with 95% confidence interval (CI) of patients with high suPAR values (≥upper tertile) are shown. Significant p-values marked bold.